Ironwood Pharmaceuticals Inc., of Cambridge, Mass., reported second-quarter U.S. net sales of Linzess, as reported by its U.S. collaboration partner, Dublin-based Allergan plc, totaling $192 million, a 14 percent increase compared to the second quarter of 2017.